cons of semaglutide Unleashing the Power Semaglutide: Revolutionizing Health and Metabolic Management Semaglutide for Weight Loss: Clinical

Contact your healthcare provider if you experience: Severe or worsening abdominal pain , particularly if it is persistent, sharp, or localized to a specific area Bloating accompanied by persistent vomiting , especially if you are unable to keep down fluids or medications Signs of gastroparesis (severely delayed gastric emptying), including feeling full after eating only small amounts, persistent nausea, vomiting undigested food several hours after eating, or unintentional weight loss beyond expected therapeutic effects Symptoms suggesting bowel obstruction or ileus , such as inability to pass gas or stool, severe abdominal distension, or cramping pain Blood in vomit or stool , which could indicate gastrointestinal bleeding Signs of pancreatitis , including severe, persistent upper abdominal pain that may radiate to the back, accompanied by nausea and vomiting Right upper quadrant pain, fever, or yellowing of the skin or eyes , which could indicate gallbladder disease (cholelithiasis or cholecystitis), a known risk with GLP-1 receptor agonists Signs of dehydration such as excessive thirst, dry mouth, dizziness, or decreased urination, which could lead to acute kidney injury if severe Additionally, seek medical advice if bloating significantly impairs your quality of life or prevents you from maintaining adequate nutrition and hydration

Website: vials.ai

Side effects with Wegovy 7.2 mg The STEP UP trial found that side effects were somewhat more common at the 7.2 mg dose than at 2.4 mg: 2 GI side effects: 70.8% (7.2 mg) vs 61.2% (2.4 mg) Dysaesthesia (tingling or numbness): 22.9% (7.2 mg) vs 6.0% (2.4 mg) Discontinuation due to side effects remained low at 3.3% The dysaesthesia finding is notable, though 85.7% of cases resolved while continuing treatment

But heres the important part: GLP-1 is not something foreign to your body its something your body is designed to produce

In the UK, the reporting of suspected side effects and drug interactions is a vital component of ongoing drug safety monitoring